Clinical pharmacist’s contribution to treatment adherence and quality of life in patients with stroke

ABSTRACT

Primary objective

The optimal treatment adherence rate among patients with stroke is low. This study aims to determine the effect of clinical pharmacists’ intervention on treatment adherence and quality of life (QOL) in patients with first-ever stroke.

Research design

This open, controlled, prospective and interventional study was conducted sequentially at two different university hospitals for 3 months. Patients in the intervention group (IG) were provided with clinical pharmacist-led education whereas the control group (CG) only received routine care.

Methods and procedures

Treatment adherence and QOL were assessed on discharge day, and in months 1 and 3 after discharge. Morisky Green Levine Adherence Scale and Stroke Specific Quality of Life Scale were employed to evaluate treatment adherence and QOL, respectively.

Main outcomes and results

Changes in treatment adherence score were higher between discharge day, 1^st and 3^rd months after discharge in IG than CG (p < 0.001). Regarding ‘energy’ and ‘work/productivity’ domains, patients’ scores in IG were higher than those from CG at months 1 and 3 after discharge (p < 0.05).

Conclusion

Clinical pharmacist-led education improves treatment adherence in patients with first-ever stroke. The clinical pharmacist might be integrated into the multidisciplinary team to improve QOL and treatment adherence.

KEYWORDS:

• Clinical pharmacist
• quality of life
• patient education
• stroke
• treatment adherence

Acknowledgments

We are thankful to all the healthcare workers in the department of neurology at Hacettepe University and Ankara University Ibn-i Sina Hospitals.

Disclosure statement

The authors report no conflict of interest.

Additional information

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.